Entero Therapeutics (NASDAQ:ENTO) Stock Price Down 2.6% – Time to Sell?

Entero Therapeutics, Inc. (NASDAQ:ENTOGet Free Report)’s stock price fell 2.6% during mid-day trading on Thursday . The company traded as low as $2.87 and last traded at $2.94. Approximately 38,995 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 2,798,922 shares. The stock had previously closed at $3.02.

Entero Therapeutics Trading Up 3.0%

The company has a market capitalization of $4.94 million, a price-to-earnings ratio of -1.84 and a beta of 1.19. The company’s 50 day simple moving average is $3.39 and its 200-day simple moving average is $3.47.

Entero Therapeutics Company Profile

(Get Free Report)

Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development.

Featured Stories

Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.